Status:
COMPLETED
The Effect Of Fesoterodine On Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects
Lead Sponsor:
Pfizer
Conditions:
Urinary Bladder, Overactive
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
This is an open-label, randomized, two-way crossover study to evaluate the steady-state effect of fesoterodine (8 mg QD) on the pharmacodynamics and pharmacokinetics of a single supratherapeutic dose ...
Eligibility Criteria
Inclusion
- Healthy male and/or female subjects between the ages of 18 and 55 years
Exclusion
- Not healthy subjects--subjects with acute or chronic medical or psychiatric conditions or laboratory abnormality
Key Trial Info
Start Date :
July 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2009
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT00914667
Start Date
July 1 2009
End Date
August 1 2009
Last Update
June 1 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
New Haven, Connecticut, United States, 06511